NASH Race No More Clear After AASLD Than Before
Executive Summary
Genfit joins Intercept in Phase III, but Tobira thinks its Phase IIb study will position it well for registrational studies. Intercept expects to get to market first in primary biliary cholangitis, which could be a significant market opportunity.
You may also be interested in...
Endpoint Selection Could Help Determine The NASH Race
Sponsors in the hotly pursued and yet untapped field of non-alcoholic steatohepatitis think that selection of different primary or co-primary endpoints could help differentiate their programs in the competitive space.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.